期刊
DRUG DISCOVERY TODAY
卷 11, 期 7-8, 页码 283-299出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2006.02.004
关键词
-
Although the 5-hydroxytryptamine(6) (5-HT6) receptor was discovered only recently, its almost exclusive distribution in the brain makes it a promising, novel, target for central nervous system (CNS)-mediated diseases such as Alzheimer's disease (cognitive function), schizophrenia, anxiety and obesity. In the past few years a significant research interest has advanced the understanding of the functional roles and the pharmacophore requirements of this receptor. Two 5-HT6 receptor antagonists have already entered Phase 11 clinical trials for the enhancement of cognitive function. Since the first discovery of selective ligands for the 5-HT6 receptor by HTS in 1998, several medicinal-chemistry-driven approaches have delivered highly selective lead structures with well-defined functionalities, starting from either the endogenous ligand 5-HT or the chemical structures identified by HTS. The concept of `scaffold hopping' has been employed to expand the variability of the available chemical scaffolds and to generate patentable ligands. Supported by pharmacophore models, which have been established recently, the binding and functionality (structure-activity relationships) of the lead structures have been optimized further.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据